Comparing Korro Bio (NASDAQ:KRRO) and Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Korro Bio (NASDAQ:KRRO) and Provectus Biopharmaceuticals (OTCMKTS:PVCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Korro Bio and Provectus Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$14.07 million	32.39	-$81.17 million	N/A	N/A
Provectus Biopharmaceuticals	$560,000.00	87.50	-$3.10 million	N/A	N/A

Provectus Biopharmaceuticals has lower revenue, but higher earnings than Korro Bio.

Profitability

This table compares Korro Bio and Provectus Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	N/A	-80.45%	-59.51%
Provectus Biopharmaceuticals	-470.05%	N/A	-188.18%

Risk & Volatility

Korro Bio has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500. Comparatively, Provectus Biopharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Insider & Institutional Ownership

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 0.1% of Provectus Biopharmaceuticals shares are held by institutional investors. 16.8% of Korro Bio shares are held by insiders. Comparatively, 12.8% of Provectus Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Korro Bio and Provectus Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	0	0	4	0	3.00
Provectus Biopharmaceuticals	0	0	0	0	N/A

Korro Bio presently has a consensus target price of $122.50, indicating a potential upside of 149.24%. Given Korro Bio’s higher probable upside, analysts clearly believe Korro Bio is more favorable than Provectus Biopharmaceuticals.

Summary

Korro Bio beats Provectus Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.